<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN" "http://jats.nlm.nih.gov/publishing/1.1d3/JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.1d3" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id>
<journal-title-group>
<journal-title>PLOS ONE</journal-title>
</journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pone.0188859</article-id>
<article-id pub-id-type="publisher-id">PONE-D-17-27677</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancer treatment</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Cell biology</subject><subj-group><subject>Cell processes</subject><subj-group><subject>Cell growth</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Cell biology</subject><subj-group><subject>Cell processes</subject><subj-group><subject>Cell death</subject><subj-group><subject>Apoptosis</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and neoplasms</subject><subj-group><subject>Sarcomas</subject><subj-group><subject>Leiomyosarcoma</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and neoplasms</subject><subj-group><subject>Sarcomas</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>DNA-binding proteins</subject><subj-group><subject>Histones</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Bioassays and physiological analysis</subject><subj-group><subject>Biochemical analysis</subject><subj-group><subject>Colorimetric assays</subject><subj-group><subject>MTS assay</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Bioassays and physiological analysis</subject><subj-group><subject>Biochemical analysis</subject><subj-group><subject>Enzyme assays</subject><subj-group><subject>MTS assay</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>People and places</subject><subj-group><subject>Geographical locations</subject><subj-group><subject>North America</subject><subj-group><subject>United States</subject><subj-group><subject>Ohio</subject></subj-group></subj-group></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>Mocetinostat combined with gemcitabine for the treatment of leiomyosarcoma: Preclinical correlates</article-title>
<alt-title alt-title-type="running-head">Mocetinostat combined with gemcitabine to treatment leiomyosarcoma</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-1337-5050</contrib-id>
<name name-style="western">
<surname>Lopez</surname>
<given-names>Gonzalo</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Resources</role>
<role content-type="http://credit.casrai.org/">Software</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Visualization</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Braggio</surname>
<given-names>Danielle</given-names>
</name>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Zewdu</surname>
<given-names>Abeba</given-names>
</name>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Software</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Casadei</surname>
<given-names>Lucia</given-names>
</name>
<role content-type="http://credit.casrai.org/">Data curation</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Batte</surname>
<given-names>Kara</given-names>
</name>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Project administration</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Bid</surname>
<given-names>Hemant Kumar</given-names>
</name>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Koller</surname>
<given-names>David</given-names>
</name>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Yu</surname>
<given-names>Peter</given-names>
</name>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Iwenofu</surname>
<given-names>Obiajulu Hans</given-names>
</name>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Visualization</role>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Strohecker</surname>
<given-names>Anne</given-names>
</name>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Choy</surname>
<given-names>Edwin</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<xref ref-type="aff" rid="aff004"><sup>4</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Lev</surname>
<given-names>Dina</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<xref ref-type="aff" rid="aff005"><sup>5</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<name name-style="western">
<surname>Pollock</surname>
<given-names>Raphael</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff006"><sup>6</sup></xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label> <addr-line>Comprehensive Cancer Center, The Ohio State University, Columbus, OH, United States of America</addr-line></aff>
<aff id="aff002"><label>2</label> <addr-line>Life Science Institute, University of Michigan, Ann Arbor, MI, United States of America</addr-line></aff>
<aff id="aff003"><label>3</label> <addr-line>Department of Pathology, The Ohio State University, Columbus, OH, United States of America</addr-line></aff>
<aff id="aff004"><label>4</label> <addr-line>Division of Hematology Oncology, Massachusetts General Hospital, Boston, MA, United States of America</addr-line></aff>
<aff id="aff005"><label>5</label> <addr-line>Surgery B, Sheba Medical Center, Tel Aviv, Israel</addr-line></aff>
<aff id="aff006"><label>6</label> <addr-line>Department of Surgery, The Ohio State University, Columbus, OH, United States of America</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>Lebedeva</surname>
<given-names>Irina V.</given-names>
</name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/>
</contrib>
</contrib-group>
<aff id="edit1"><addr-line>Columbia University, UNITED STATES</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>The authors have declared that no competing interests exist.</p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">raphael.pollock@osumc.edu</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>29</day>
<month>11</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<year>2017</year>
</pub-date>
<volume>12</volume>
<issue>11</issue>
<elocation-id>e0188859</elocation-id>
<history>
<date date-type="received">
<day>10</day>
<month>8</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>14</day>
<month>11</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-year>2017</copyright-year>
<copyright-holder>Lopez et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pone.0188859"/>
<abstract>
<p>Leiomyosarcoma (LMS) is a malignant soft tissue sarcoma (STS) with a dismal prognosis following metastatic disease. Chemotherapeutic intervention has demonstrated to have modest clinical efficacy with no curative potential in LMS patients. Previously, we demonstrated pan-HDAC inhibition to have a superior effect in various complex karyotypic sarcomas. In this study, our goal is to evaluate the therapeutic efficacy of mocetinostat alone and in combination with gemcitabine in LMS. Human leiomyosarcoma (LMS) cell lines were used for <italic>in vitro</italic> and <italic>in vivo</italic> studies. Compounds tested included the class I HDAC inhibitor, mocetinostat, and nucleoside analog, gemcitabine. MTS and clonogenic assays were used to evaluate the effect of mocetinostat on LMS cell growth. Cleaved caspase 3/7 analysis was used to determine the effects of mocetinostat on apoptosis. Compusyn software was used to determine <italic>in vitro</italic> synergy studies for the combination of mocetinostat plus gemcitabine. A LMS xenograft model in SCID mice was used to test the impact of mocetinostat alone, gemcitabine alone and the combination of mocetinostat plus gemcitabine. Mocetinostat abrogated LMS cell growth and clonogenic potential, and enhanced apoptosis in LMS cell lines. The combination of mocetinostat plus gemcitabine exhibited a synergistic effect in LMS cells <italic>in vitro</italic>. Similarly, mocetinostat combined with gemcitabine resulted in superior anti-LMS effects <italic>in vivo</italic>. Mocetinostat reduced the expression of gemcitabine-resistance markers RRM1, RRM2, and increased the expression of gemcitabine-sensitivity marker, hENT1, in LMS cells. LMS are aggressive, metastatic tumors with poor prognosis where effective therapeutic interventions are wanting. Our studies demonstrate the potential utility of mocetinostat combined with gemcitabine for the treatment of LMS.</p>
</abstract>
<funding-group>
<award-group id="award001">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000054</institution-id>
<institution>National Cancer Institute</institution>
</institution-wrap>
</funding-source>
<award-id>U54CA168512</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Pollock</surname>
<given-names>Raphael</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award002">
<funding-source>
<institution>National Leiomyosarcoma Foundation</institution>
</funding-source>
<award-id>GRT00041181/60052311</award-id>
<principal-award-recipient>
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-1337-5050</contrib-id>
<name name-style="western">
<surname>Lopez</surname>
<given-names>Gonzalo</given-names>
</name>
</principal-award-recipient>
</award-group>
<funding-statement>This work was supported by NIH SARC SPORE grant (U54CA168512), funding recipient RP; and National Leiomyosarcoma Foundation grant (GRT00041181/60052311), funding recipient GL. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
</funding-group>
<counts>
<fig-count count="4"/>
<table-count count="0"/>
<page-count count="13"/>
</counts>
<custom-meta-group>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec001" sec-type="intro">
<title>Introduction</title>
<p>Leiomyosarcoma (LMS) is a malignant tumor of mesenchymal origin, and is one of the most common soft tissue sarcoma subtypes. LMS can present in various locations including the uterus, skin, blood vessels, retroperitoneum, gastrointestinal tract, trunk, and extremities [<xref ref-type="bibr" rid="pone.0188859.ref001">1</xref>]. The pathogenesis of LMS remains largely unknown, with complex karyotype and both intra- and intertumor heterogeneity [<xref ref-type="bibr" rid="pone.0188859.ref002">2</xref>]. Advanced-stage LMS is usually incurable with current systemic therapies, suggesting the need for novel antitumor strategies [<xref ref-type="bibr" rid="pone.0188859.ref001">1</xref>].</p>
<p>A common LMS systemic therapeutic option includes gemcitabine (2’,2’-difluorodeoxycytidine) combined with docetaxel [<xref ref-type="bibr" rid="pone.0188859.ref003">3</xref>]. Gemcitabine is a fluorinated analogue of the nucleoside deoxycytidine. Intracellular phosphorylation of gemcitabine leads to an active diphosphate form which inhibits ribonucleotide reductase and an active triphosphate form which is incorporated into DNA [<xref ref-type="bibr" rid="pone.0188859.ref004">4</xref>]. Administration of gemcitabine alone was reported to have a response rate of 21% in second-line therapy in uterine LMS based on Gynecological Oncology Group (GOG) response criteria [<xref ref-type="bibr" rid="pone.0188859.ref005">5</xref>]. In a phase II study, gemcitabine combined with docetaxel showed a response rate of 25% by RECIST criteria [<xref ref-type="bibr" rid="pone.0188859.ref006">6</xref>]. Even in the first-line setting, a phase II trial of locally advanced/metastatic LMS demonstrated that gemcitabine combined with docetaxel was active [<xref ref-type="bibr" rid="pone.0188859.ref007">7</xref>]. The combination of gemcitabine and docetaxel are synergistic [<xref ref-type="bibr" rid="pone.0188859.ref008">8</xref>], raising the possibility that gemcitabine be synergistic with other anticancer therapeutics as well.</p>
<p>One antitumor strategy of growing interest are histone deacetylases (HDAC) inhibitors [<xref ref-type="bibr" rid="pone.0188859.ref009">9</xref>]. HDACs play a crucial role in chromatin remodeling and gene regulation; histone acetylation of lysines in histone tails is associated with a condensed chromatin state and gene silencing [<xref ref-type="bibr" rid="pone.0188859.ref010">10</xref>]. Inhibition of this process leads to a more relaxed chromatin state and active gene transcription [<xref ref-type="bibr" rid="pone.0188859.ref011">11</xref>]. There are 11 isoforms of HDACs which are grouped into 4 different classes, and many inhibitors have been developed which can inhibit various HDAC isoforms [<xref ref-type="bibr" rid="pone.0188859.ref012">12</xref>]. Mocetinostat is a class I and IV selective HDAC inhibitor which has shown potent and selective antiproliferative effects in various human cancer cells preclinically [<xref ref-type="bibr" rid="pone.0188859.ref013">13</xref>]. Clinical trials show that mocetinostat is well-tolerated, with favorable pharmacokinetics and pharmacodynamics and promising antitumor activity in several hematological diseases [<xref ref-type="bibr" rid="pone.0188859.ref014">14</xref>]. Combining mocetinostat with other antitumor agents for the treatment of solid tumors is an additional promising approach [<xref ref-type="bibr" rid="pone.0188859.ref015">15</xref>].</p>
<p>In this study we examined a combination of mocetinostat and gemcitabine in the treatment of LMS. In addition to elucidating the <italic>in vitro</italic> anticancer effects, we used an established LMS xenograft model to study the combination effects of gemcitabine and mocetinostat <italic>in vivo</italic>. Our results demonstrate synergistic anti-LMS effects of combined gemcitabine and Mocetinostat, an approach that warrants further study.</p>
</sec>
<sec id="sec002" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="sec003">
<title>Cell lines and reagents</title>
<p>The human LMS cell lines SKLMS1 (ATCC) and LMS1 (Dominique Broccoli, Mercer University, Savannah, GA) was used in this study. LMS cell strains Leio-012 and Leio-196A were developed at the University of Texas MD Anderson Cancer Center/MDACC (Houston, TX) under IRB approval from MDACC and with patient written informed consent. LMS-117 was developed in the Sarcoma Research Lab (The Ohio State University, Columbus, OH) under IRB approval from The Ohio State University and with patient written informed consent. LMS1 was developed in Dr. Dominique Broccoli’s lab (Mercer University, Savannah, GA) and acquired via collaboration; no identifying patient information was provided when acquiring LMS1. To establish LMS cell strains, patient tumor tissue was acquired at surgery and tumor tissue was digested using 3% collagenase Type I, 0.02% DNAse I Type II, and 1.5 mg/mL hyaluronidase. The digested tumor was strained and centrifuged at 1500 RPM for 5 minutes at room temperature, the cell pellet was washed once with sterile PBS and centrifuged again. The cell pellet was resuspended and maintained in DMEM 1X media supplemented with 10% FBS and Primocin. Short Tandem Repeat (STR) analysis was used to confirm the cell origin to the corresponding patient tumor (<xref ref-type="supplementary-material" rid="pone.0188859.s002">S1 Table</xref>). Control cell lines, human aortic smooth muscle cells (HASMC) and human colonic smooth muscle cells (HCSMC) were used and maintained per supplier protocol (ScienCell). Antibodies used for Western blot analysis: acetylated histone 3 (EMD Millipore), acetylated histone 4 (EMD Millipore), acetylated tubulin (Sigma), RRM1 (Abcam), RRM2 (Abcam), hENT1 (Santa Cruz Biotechnology), β-actin (Santa Cruz Biotechnology), GAPDH (Santa Cruz Biotechnology).</p>
</sec>
<sec id="sec004">
<title>Cell growth assays</title>
<p>Cell growth conducted via MTS analysis (CellTiter96 Aqueous Non-Radioactive Cell Proliferation Assay kit, Promega) per manufacturer protocol. Cells were plated at 5,000 cells per well and allowed to adhere overnight. Growth rates were assessed 96 hr after treatment with DMSO (control), or 0.1, 0.5, 1 μM of mocetinostat and absorbances measured at 490 nm wavelength. Clonogenic analysis was conducted by plating 400 cells per well. On the following day, cells were treated with DMSO or mocetinostat for 24 hr. Cells were grown for 10 days. On day 10, colonies were stained with 0.5% crystal violet solution for 30 min at RT. Crystal violet solution was removed, wells washed 5x with deionized H2O, stained colonies were scanned and counted. Drug synergy studies were conducted using MTS and analysis was conducted using Compusyn software [<xref ref-type="bibr" rid="pone.0188859.ref016">16</xref>].</p>
</sec>
<sec id="sec005">
<title>Apoptosis assays</title>
<p>Apoptosis was determined by quantifying cleaved caspase 3 and cleaved caspase 7 activity using Cell Event Caspase 3/7 Green Detection Reagent (Life Technologies) analyzed in the IncuCyte Zoom (Essen BioScience). Cells were plated at 2000 cells per well and treated with the Caspase 3/7 reagent together with DMSO or varying concentrations of mocetinostat for 96 hr. Endpoint analysis was performed in each well using Vybrant DyeCycle Green Stain (Life Technologies) in complete DMEM media.</p>
</sec>
<sec id="sec006">
<title><italic>In vivo</italic> experiment</title>
<p>Six week old female SCID mice (n = 40) weighing approximately (AVG±SD) 20±0.9 grams (Taconic Biosciences, Hudson, NY) were injected s.c. with SKLMS1 (1 x 10<sup>6</sup>) into the right flank. Once tumors reached approximately 0.5 cm, mice were randomized into four treatment arms (n = 9 per treatment arm) and treatment was initiated: Vehicle (PEG400/0.2 N HCl), mocetinostat (50 mg/kg PO QD) (Mirati Therapeutics, Inc.), gemcitabine (20 mg/kg, i.p. BID) (Selleck Chemicals), mocetinostat combined with gemcitabine. Mice in the ‘mocetinostat combined with gemcitabine’ treatment arm were given mocetinostat 24 hr prior to combining with gemcitabine. Four mice were excluded from experimentation due to low tumor take. Drug doses were used per manufacture recommendation. Mice were monitored for well being, weighed, and tumors were measured twice weekly. Animals appeared to be in good health with no significant weight loss or death observed during the course of the experiment. Ulceration occurred in some mice at the tumor site nearing the 1.5 cm endpoint; mice were provided with buprenorphine (0.05–0.1 mg/kg) as analgesic. Mice were humanely euthanized (euthanized by CO2 followed by cervical dislocation to ensure death according to IACUC guidelines) once tumors in control mice grew to approximately 1.5 cm. Final tumor volumes and weights were measured. All mice were maintained under barrier conditions at a temperature of 72°F±4°F and 12∶12 hr light:dark cycle. Mice (n = 5/cage) were housed in 194×178×397 mm cages (NexGen caging, Allentown Inc, Allentown, NJ) given feed (Harlan Teklad Irradiated diet 7912, Envigo, Huntingdon, UK) and water <italic>ad libitum</italic>. Environmental enrichment included bedding (1/4” corn cob) and autoclaved nesting material. All procedures were conducted under The Ohio State University’s Institutional Animal Care and Use Committee (IACUC) approval (number 2014A00000085) and in accordance with The Ohio State University’s Animal Welfare Assurance (number A3261-01). All sections of this report adhere to the ARRIVE Guidelines for reporting animal research [<xref ref-type="bibr" rid="pone.0188859.ref017">17</xref>]. A completed ARRIVE guidelines checklist is included in <xref ref-type="supplementary-material" rid="pone.0188859.s001">S1 Checklist</xref>.</p>
</sec>
<sec id="sec007">
<title>Statistical analysis</title>
<p>Statistical analysis was performed using GraphPad Prism6. Mean ± SEM was calculated for all <italic>in vitro</italic> and <italic>in vivo</italic> assays using ANOVA. Significance was set at * (<italic>p</italic>≤0.05), ** (<italic>p</italic>≤0.01), *** (<italic>p</italic>≤0.001), **** (<italic>p</italic>≤0.0001). Median values and confidence interval (95%) for all data are located in the <xref ref-type="supplementary-material" rid="pone.0188859.s003">S2 Table</xref>.</p>
</sec>
</sec>
<sec id="sec008" sec-type="results">
<title>Results</title>
<sec id="sec009">
<title>Mocetinostat abrogates cell growth and induces apoptosis in LMS cells</title>
<p>The class I HDAC inhibitor, mocetinostat was used in all experiments. We previously demonstrated the efficacy of the pan-HDAC inhibitor abexinostat/PCI-24781 on a subset of STS cell lines, including the leiomyosarcoma cell line SKLMS1 [<xref ref-type="bibr" rid="pone.0188859.ref018">18</xref>, <xref ref-type="bibr" rid="pone.0188859.ref019">19</xref>]. Pan-HDAC inhibitors, per abexinostat, demonstrate a high affinity to class I HDAC isoforms; e.g., HDAC1 and HDAC2 [<xref ref-type="bibr" rid="pone.0188859.ref020">20</xref>]. Pan-HDAC inhibitors yield numerous undesirable side effects, whereas the inhibition of various HDAC isoforms results in improved therapeutic windows and less toxicity [<xref ref-type="bibr" rid="pone.0188859.ref021">21</xref>], thus providing an impetus to target a smaller set, i.e., class I HDACs in LMS. Mocetinostat increased LMS cell line/strain histone 3 and 4 acetylation in a dose- and time-depended manner (<xref ref-type="fig" rid="pone.0188859.g001">Fig 1A</xref>). Tubulin acetylation, a HDAC6 substrate, remained unacetylated upon treatment with mocetinostat, demonstrating the compound’s affinity to class I <italic>vs</italic> class II HDAC substrates. The effect of mocetinostat on LMS cell growth was tested. Mocetinostat abrogated cell growth in a time- and dose-dependent manner (<xref ref-type="fig" rid="pone.0188859.g001">Fig 1B</xref> and <xref ref-type="supplementary-material" rid="pone.0188859.s004">S3 Table</xref>). LMS1 and Leio-196A demonstrated sensitivity to mocetinostat followed by LMS-117; SKLMS1 and Leio-012 exhibited the highest tolerance among the LMS cells. Mocetinostat had a modest impact on normal cells (HASMC and HCSMC). Mocetinostat significantly reduced LMS clonogenic potential in LMS1 and SKLMS1 cells (<xref ref-type="fig" rid="pone.0188859.g001">Fig 1C</xref>). Again, LMS1 exhibited sensitivity whereas SKLMS1 was more tolerant to mocetinostat anti-cancer effects.</p>
<fig id="pone.0188859.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0188859.g001</object-id>
<label>Fig 1</label>
<caption>
<title>Mocetinostat inhibits LMS cell growth and induces apoptosis.</title>
<p>A, Mocetinostat increased acetylated histone 3 and 4 in a time- and dose-dependent manner in LMS cells. Mocetinostat did not increase acetylated tubulin expression. B, Mocetinostat-induced growth inhibition was determined using MTS assays. C, Colony formation assays recapitulate the sensitivity and tolerant dichotomy between LMS1 and SKLMS1 to mocetinostat treatment. D, Mocetinostat induced a significant increase in cleaved caspase 3/7 in LMS1 cells and a modest increase in SKLMS1 cells.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0188859.g001" xlink:type="simple"/>
</fig>
<p>To further assess the impact of mocetinostat on LMS cell proliferation, we evaluated the compound’s effect on apoptosis. Cleaved caspase 3/7 activity in LMS cells treated with mocetinostat was measured using the IncuCyte Zoom system. A similar trend in drug sensitivity was observed in LMS cells in response to caspase 3/7 activity (<xref ref-type="fig" rid="pone.0188859.g001">Fig 1D</xref>); LMS1 displaying a significant increase in cleaved caspase 3/7 and SKLMS1 displaying a modest cleaved caspase 3/7 increase in response to mocetinostat.</p>
</sec>
<sec id="sec010">
<title>Mocetinostat combined with gemcitabine exhibits a synergistic anti-LMS effect in vitro</title>
<p>Previously, we identified superior anti-STS effects when combining pan-HDAC inhibition (abexinostat) with doxorubicin or cisplatin [<xref ref-type="bibr" rid="pone.0188859.ref018">18</xref>] <italic>in vitro</italic> and <italic>in vivo</italic>. In this study we evaluated the efficacy of mocetinostat combined with gemcitabine. SKLMS1 and LMS1 were used as representative cell lines that were tolerant/sensitive in response to mocetinostat. Cells were pretreated with mocetinostat 24 hr prior to combining with gemcitabine. The combination of mocetinostat and gemcitabine in this dosage sequence exhibited a synergistic effect in both cell lines (<xref ref-type="fig" rid="pone.0188859.g002">Fig 2A and 2B</xref>). No synergy was identified when the cells were pretreated with gemcitabine prior to combining with mocetinostat or when both drugs were administered concurrently (data not shown). The combination effects on apoptosis were evaluated next. SKLMS1 cells were pretreated with mocetinostat then combined with gemcitabine and analyzed for caspase 3/7 activity using the Incucyte Zoom. The data demonstrates a significant pro-apoptotic effect in cells treated with the combination versus either drug alone (<xref ref-type="fig" rid="pone.0188859.g002">Fig 2C</xref>). These <italic>in vitro</italic> findings lead us to test this combination <italic>in vivo</italic>.</p>
<fig id="pone.0188859.g002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0188859.g002</object-id>
<label>Fig 2</label>
<caption>
<title>Mocetinostat synergizes with gemcitabine in LMS cells <italic>in vitro</italic>.</title>
<p>A and B, MTS assays demonstrating synergistic combination of mocetinostat and gemcitabine in SKLMS1 and LMS cells, respectively (cells were pretreated with mocetinostat prior to combining with gemcitabine). C, Mocetinostat combined with gemcitabine enhances caspase 3/7 positive SKLMS1 cells. Combination index (CI) values of the drug combinations were calculated using Compusyn software. Synergy, additivity, and antagonism are defined as CI &lt; 1, CI = 1, and CI &gt; 1, respectively.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0188859.g002" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec011">
<title>Mocetinostat combined with gemcitabine versus either drug alone demonstrates a superior anti-LMS effect <italic>in vivo</italic></title>
<p>SKLMS1 xenografts were used for <italic>in vivo</italic> testing of mocetinostat combined with gemcitabine in that LMS1 cells failed to grow as xenografts in SCID mice. Once tumors reached approximately 100 mm<sup>3</sup>, mocetinostat was administered i.p. daily at a dose of 50 mg/kg to mice in the mocetinostat alone and mocetinostat plus gemcitabine groups. The treatments were well tolerated without significant weight loss. Treatment with mocetinostat alone did not significantly affect SKLMS1 tumor growth, whereas gemcitabine alone induced significant tumor growth inhibition (<italic>p</italic> ≤ 0.0001). Mocetinostat combined with gemcitabine significantly inhibited SKLMS1 tumor growth compared to either treatment alone (<xref ref-type="fig" rid="pone.0188859.g003">Fig 3</xref>; <italic>p</italic> ≤ 0.0001). The average tumor weights at the end of the study were: 0.29 g ±0.03 for vehicle, 0.27 g ±0.03 for mocetinostat alone, 0.12 g ±0.02 for gemcitabine alone, and 0.05 g ± 0.01 for the combination (<xref ref-type="fig" rid="pone.0188859.g003">Fig 3</xref>). Mocetinostat alone modestly reduced tumor weight, while gemcitabine alone (<italic>p</italic> ≤ 0.0001) and the drug combination significantly (<italic>p</italic> ≤ 0.0001) reduced SKLMS1 tumor weight compared to vehicle.</p>
<fig id="pone.0188859.g003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0188859.g003</object-id>
<label>Fig 3</label>
<caption>
<title>Mocetinostat combined with gemcitabine exhibits significant anti-LMS effect <italic>in vivo</italic>.</title>
<p>Mocetinostat combined with gemcitabine significantly reduced tumor growth and tumor weight.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0188859.g003" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec012">
<title>Mocetinostat reduces gemcitabine-resistance associated target expression <italic>in vitro</italic> and <italic>in vivo</italic></title>
<p>To identify potential mechanisms of mocetinostat-induced sensitization to gemcitabine, LMS cells were treated with mocetinostat and immunoblotted for the key gemcitabine-resistant targets, RRM1, RRM2, and hENT1 [<xref ref-type="bibr" rid="pone.0188859.ref022">22</xref>, <xref ref-type="bibr" rid="pone.0188859.ref023">23</xref>], demonstrating mocetinostat-induced down-regulation of RRM1, RRM2, and an increase in hENT1 protein expression in LMS cells (<xref ref-type="fig" rid="pone.0188859.g004">Fig 4</xref>). Mocetinostat-induced regulation of these proteins may contribute to the observed synergistic sensitization to gemcitabine <italic>in vitro</italic> and <italic>in vivo</italic>, and this direction is being evaluated by us at this time.</p>
<fig id="pone.0188859.g004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0188859.g004</object-id>
<label>Fig 4</label>
<caption>
<title>Mocetinostat regulates gemcitabine-resistant markers expression.</title>
<p>Mocetinostat reduces RRM1 and RRM2, and increases hENT1 expression in LMS cell lines.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0188859.g004" xlink:type="simple"/>
</fig>
</sec>
</sec>
<sec id="sec013" sec-type="conclusions">
<title>Discussion</title>
<p>Our investigations demonstrate anti-LMS synergy using the combination of mocetinostat and gemcitabine. Our preclinical data explores a novel therapeutic approach for the treatment of LMS. The role of gemcitabine in sarcoma is limited. Initially, gemcitabine was shown to have benefit for the treatment of chemo-resistant osteosarcoma [<xref ref-type="bibr" rid="pone.0188859.ref024">24</xref>], leading the way for various clinical trials in sarcomas of different histologies. The trials demonstrate uterine LMS (ULMS) to respond best to gemcitabine compared to non-uterine LMS and STS of different histology [<xref ref-type="bibr" rid="pone.0188859.ref008">8</xref>]. Recently, markers associated with gemcitabine resistance were shown to be upregulated in a cohort of ULMS patient samples [<xref ref-type="bibr" rid="pone.0188859.ref025">25</xref>]. Studies focusing on the role of HDAC inhibition in STS warrants further investigation, especially in the context of LMS [<xref ref-type="bibr" rid="pone.0188859.ref018">18</xref>, <xref ref-type="bibr" rid="pone.0188859.ref026">26</xref>, <xref ref-type="bibr" rid="pone.0188859.ref027">27</xref>].</p>
<p>The efficacy of HDAC inhibition combined with gemcitabine has been previously described in various tumor models [<xref ref-type="bibr" rid="pone.0188859.ref028">28</xref>–<xref ref-type="bibr" rid="pone.0188859.ref041">41</xref>]. Extensive examination of gemcitabine resistance in pancreatic cancer has yielded strategies to overcome gemcitabine resistance using rational combination therapies, including several classes of HDAC inhibitor compounds. Similar to our study, Sung et al. demonstrated the synergistic efficacy of mocetinostat in combination with gemcitabine in human pancreatic cancer cells [<xref ref-type="bibr" rid="pone.0188859.ref042">42</xref>]. Gemcitabine resistant cells have been shown to be sensitive to HDAC inhibition [<xref ref-type="bibr" rid="pone.0188859.ref043">43</xref>]. Recently, Lee et al., demonstrated that the novel HDAC inhibitor, CG200745, reduced the expression of multidrug-resistant protein MRP4 in pancreatic cells, suggesting a potential synergistic mechanism of HDAC inhibition combined with gemcitabine [<xref ref-type="bibr" rid="pone.0188859.ref044">44</xref>].</p>
<p>Pan-HDAC inhibitors exhibit side effects prompting the development of isoform-specific HDAC inhibitors, with the aim of reducing toxicities while enhancing the therapeutic window. Gong et al. demonstrated the effective combination of sirtuin 1 (SIRT1) inhibition and gemcitabine in pancreatic carcinoma. Sirtuin 1 is one of seven NAD-dependent deacetylase isoforms [<xref ref-type="bibr" rid="pone.0188859.ref045">45</xref>], suggesting that the combination of HDAC/SIRT isoform-specific inhibition and gemcitabine may warrant further investigation.</p>
<p>Epigenetic regulation of acquired gemcitabine resistance has been described [<xref ref-type="bibr" rid="pone.0188859.ref046">46</xref>–<xref ref-type="bibr" rid="pone.0188859.ref049">49</xref>]. HDAC inhibition may be crucial to help establish potential epigenetic markers of LMS gemcitabine resistance that can be targeted for therapy. Essential proteins that have a role in gemcitabine resistance include RRM1, RRM2, and hENT1. We have demonstrated mocetinostat-induced regulation of these proteins, suggesting a potential mechanism of mocetinostat-induced sensitivity to gemcitabine. In LMS, RRM1 is more highly expressed in uterine LMS versus extrauterine LMS patients [<xref ref-type="bibr" rid="pone.0188859.ref025">25</xref>], a possible biological dichotomy relevant to therapeutic intervention. The roles of RRM2 and hENT1 in the context of gemcitabine resistance in leiomyosarcoma have yet to be identified, and are currently under study in our laboratory.</p>
<p>Our work expands the knowledge base needed to identify potentially novel therapeutic options for the treatment of leiomyosarcoma, especially in the context of chemotherapeutic resistance. This work also identifies novel LMS cell lines; there is a major lack of available LMS cell lines at this time. This study presents a platform to further study the mechanistic role of HDAC inhibition and gemcitabine resistance in LMS. Accordingly, we currently investigating isoform-specific HDAC inhibition combined with gemcitabine to determine the utility of specific HDAC isoforms in anti-LMS therapy, including their potential synergism with gemcitabine as per above. These studies also utilize several LMS patient-derived xenograft (PDX) models we have recently developed as a preclinical bridge to future clinical trials to evaluate these severely needed and promising new approach to LMS patent therapeutics.</p>
</sec>
<sec id="sec014">
<title>Supporting information</title>
<supplementary-material id="pone.0188859.s001" mimetype="application/pdf" position="float" xlink:href="info:doi/10.1371/journal.pone.0188859.s001" xlink:type="simple">
<label>S1 Checklist</label>
<caption>
<title>The ARRIVE guidelines checklist.</title>
<p>(PDF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0188859.s002" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet" position="float" xlink:href="info:doi/10.1371/journal.pone.0188859.s002" xlink:type="simple">
<label>S1 Table</label>
<caption>
<title>STR analysis of LMS cell lines compared to their corresponding patient tumor.</title>
<p>(XLSX)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0188859.s003" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet" position="float" xlink:href="info:doi/10.1371/journal.pone.0188859.s003" xlink:type="simple">
<label>S2 Table</label>
<caption>
<title>Median values and confidence intervals (95%).</title>
<p>(XLSX)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0188859.s004" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet" position="float" xlink:href="info:doi/10.1371/journal.pone.0188859.s004" xlink:type="simple">
<label>S3 Table</label>
<caption>
<title>EC50 of mocetinostat on cell lines.</title>
<p>(XLSX)</p>
</caption>
</supplementary-material>
</sec>
</body>
<back>
<ack>
<p>We would like to acknowledge Dr. Nyla Heerema and Jadwiga Labanowska for karyotyping analysis, the OSU Plant-Microbe Genomics Facility for STR analysis, the National Leiomyosarcoma Foundation/NLMSF (GRT00041181/60052311), and the SARC SPORE (U54CA168512).</p>
</ack>
<ref-list>
<title>References</title>
<ref id="pone.0188859.ref001"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wang</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Shi</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Naing</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Janku</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Subbiah</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Araujo</surname> <given-names>DM</given-names></name>, <etal>et al</etal>. <article-title>Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience</article-title>. <source>Cancer Med</source>. <year>2016</year>;<volume>5</volume>: <fpage>3437</fpage>–<lpage>3444</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/cam4.956" xlink:type="simple">10.1002/cam4.956</ext-link></comment> <object-id pub-id-type="pmid">27882721</object-id></mixed-citation></ref>
<ref id="pone.0188859.ref002"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wang</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Lu</surname> <given-names>YJ</given-names></name>, <name name-style="western"><surname>Fisher</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Bridge</surname> <given-names>JA</given-names></name>, <name name-style="western"><surname>Shipley</surname> <given-names>J</given-names></name>. <article-title>Characterization of chromosome aberrations associated with soft-tissue leiomyosarcomas by twenty-four-color karyotyping and comparative genomic hybridization analysis</article-title>. <source>Genes Chromosomes Cancer</source>. <year>2001</year>;<volume>31</volume>: <fpage>54</fpage>–<lpage>64</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/gcc.1118" xlink:type="simple">10.1002/gcc.1118</ext-link></comment> <object-id pub-id-type="pmid">11284036</object-id></mixed-citation></ref>
<ref id="pone.0188859.ref003"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hensley</surname> <given-names>ML</given-names></name>, <name name-style="western"><surname>Maki</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Venkatraman</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Geller</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Lovegren</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Aghajanian</surname> <given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial</article-title>. <source>J Clin Oncol</source>. <year>2002</year>;<volume>20</volume>: <fpage>2824</fpage>–<lpage>2831</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1200/JCO.2002.11.050" xlink:type="simple">10.1200/JCO.2002.11.050</ext-link></comment> <object-id pub-id-type="pmid">12065559</object-id></mixed-citation></ref>
<ref id="pone.0188859.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Heinemann</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Hertel</surname> <given-names>L W</given-names></name>, <name name-style="western"><surname>Grindey</surname> <given-names>G B</given-names></name>, <name name-style="western"><surname>Plunkett</surname> <given-names>W</given-names></name>. <article-title>Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine</article-title>. <source>Cancer Res</source>. <year>1988</year>;<volume>48</volume>: <fpage>4024</fpage>–<lpage>4031</lpage>. <object-id pub-id-type="pmid">3383195</object-id></mixed-citation></ref>
<ref id="pone.0188859.ref005"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Look</surname> <given-names>KY</given-names></name>, <name name-style="western"><surname>Sandler</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Blessing</surname> <given-names>JA</given-names></name>, <name name-style="western"><surname>Lucci</surname> <given-names>JA</given-names> <suffix>3rd</suffix></name>, <name name-style="western"><surname>Rose</surname> <given-names>PG</given-names></name>, <name name-style="western"><surname>Gynecologic Oncology Group</surname> <given-names>S</given-names></name>. <article-title>Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study</article-title>. <source>Gynec Oncol</source>. <year>2004</year>;<volume>92</volume>: <fpage>644</fpage>–<lpage>647</lpage>.</mixed-citation></ref>
<ref id="pone.0188859.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Seddon</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Scurr</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Jones</surname> <given-names>RL</given-names></name>, <name name-style="western"><surname>Wood</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Propert-Lewis</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Fisher</surname> <given-names>C</given-names></name>, <etal>et al</etal>. <article-title>A phase II trial to assess the activity of gemcitabine and docetaxel as first line chemotherapy treatment in patients with unresectable leiomyosarcoma</article-title>. <source>Clin Sarcoma Res</source>. <year>2015</year>;<volume>5</volume>: <fpage>13</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/s13569-015-0029-8" xlink:type="simple">10.1186/s13569-015-0029-8</ext-link></comment> <object-id pub-id-type="pmid">25987978</object-id></mixed-citation></ref>
<ref id="pone.0188859.ref007"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hensley</surname> <given-names>ML</given-names></name>, <name name-style="western"><surname>Blessing</surname> <given-names>JA</given-names></name>, <name name-style="western"><surname>Mannel</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Rose</surname> <given-names>PG</given-names></name>. <article-title>Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial</article-title>. <source>Gynecol Oncol</source>. <year>2008</year>;<volume>109</volume>: <fpage>329</fpage>–<lpage>34</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ygyno.2008.03.010" xlink:type="simple">10.1016/j.ygyno.2008.03.010</ext-link></comment> <object-id pub-id-type="pmid">18534250</object-id></mixed-citation></ref>
<ref id="pone.0188859.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Maki</surname> <given-names>RG</given-names></name>. <article-title>Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future</article-title>. <source>Oncologist</source>. <year>2007</year>;<volume>12</volume>: <fpage>999</fpage>–<lpage>1006</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1634/theoncologist.12-8-999" xlink:type="simple">10.1634/theoncologist.12-8-999</ext-link></comment> <object-id pub-id-type="pmid">17766660</object-id></mixed-citation></ref>
<ref id="pone.0188859.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>West</surname> <given-names>AC</given-names></name>, <name name-style="western"><surname>Johnstone</surname> <given-names>RW</given-names></name>. <article-title>New and emerging HDAC inhibitors for cancer treatment</article-title>. <source>J Clin Invest</source>. <year>2014</year>; <volume>124</volume>: <fpage>30</fpage>–<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1172/JCI69738" xlink:type="simple">10.1172/JCI69738</ext-link></comment> <object-id pub-id-type="pmid">24382387</object-id></mixed-citation></ref>
<ref id="pone.0188859.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Iizuka</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Smith</surname> <given-names>MM</given-names></name>. <article-title>Functional consequences of histone modifications</article-title>. <source>Curr Opin Genet Dev</source>. <year>2003</year>;<volume>13</volume>: <fpage>154</fpage>–<lpage>160</lpage>. <object-id pub-id-type="pmid">12672492</object-id></mixed-citation></ref>
<ref id="pone.0188859.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Johnstone</surname> <given-names>RW</given-names></name>. <article-title>Histone-deacetylase inhibitors: novel drugs for the treatment of cancer</article-title>. <source>Nat Rev Drug Disc</source>. <year>2002</year>;<volume>1</volume>: <fpage>287</fpage>–<lpage>299</lpage>.</mixed-citation></ref>
<ref id="pone.0188859.ref012"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Haberland</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Montgomery</surname> <given-names>RL</given-names></name>, <name name-style="western"><surname>Olson</surname> <given-names>EN</given-names></name>. <article-title>The many roles of histone deacetylases in development and physiology: implications for disease and therapy</article-title>. <source>Nat Rev Genet</source>. <year>2009</year>;<volume>10</volume>: <fpage>32</fpage>–<lpage>42</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nrg2485" xlink:type="simple">10.1038/nrg2485</ext-link></comment> <object-id pub-id-type="pmid">19065135</object-id></mixed-citation></ref>
<ref id="pone.0188859.ref013"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Fournel</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Bonfils</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Hou</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Yan</surname> <given-names>PT</given-names></name>, <name name-style="western"><surname>Trachy-Bourget</surname> <given-names>MC</given-names></name>, <name name-style="western"><surname>Kalita</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo</article-title>. <source>Mol Cancer Ther</source>. <year>2008</year>;<volume>7</volume>: <fpage>759</fpage>–<lpage>68</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1158/1535-7163.MCT-07-2026" xlink:type="simple">10.1158/1535-7163.MCT-07-2026</ext-link></comment> <object-id pub-id-type="pmid">18413790</object-id></mixed-citation></ref>
<ref id="pone.0188859.ref014"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Boumber</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Younes</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Garcia-Manero</surname> <given-names>G</given-names></name>. <article-title>Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor</article-title>. <source>Expert Opin Investig Drugs</source>. <year>2011</year>;<volume>20</volume>: <fpage>823</fpage>–<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1517/13543784.2011.577737" xlink:type="simple">10.1517/13543784.2011.577737</ext-link></comment> <object-id pub-id-type="pmid">21554162</object-id></mixed-citation></ref>
<ref id="pone.0188859.ref015"><label>15</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Siu</surname> <given-names>LL</given-names></name>, <name name-style="western"><surname>Pili</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Duran</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Messersmith</surname> <given-names>WA</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>EX</given-names></name>, <name name-style="western"><surname>Sullivan</surname> <given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors</article-title>. <source>J Clin Oncol</source>. <year>2008</year>;<volume>26</volume>: <fpage>1940</fpage>–<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1200/JCO.2007.14.5730" xlink:type="simple">10.1200/JCO.2007.14.5730</ext-link></comment> <object-id pub-id-type="pmid">18421048</object-id></mixed-citation></ref>
<ref id="pone.0188859.ref016"><label>16</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chou</surname> <given-names>T</given-names></name>. <article-title>Drug combination studies and their synergy quantification using the Chou-Talalay method</article-title>. <source>Cancer Res</source>. <year>2010</year>;<volume>70</volume>: <fpage>440</fpage>–<lpage>46</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1158/0008-5472.CAN-09-1947" xlink:type="simple">10.1158/0008-5472.CAN-09-1947</ext-link></comment> <object-id pub-id-type="pmid">20068163</object-id></mixed-citation></ref>
<ref id="pone.0188859.ref017"><label>17</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kilkenny</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Browne</surname> <given-names>WJ</given-names></name>, <name name-style="western"><surname>Cuthill</surname> <given-names>IC</given-names></name>, <name name-style="western"><surname>Emerson</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Altman</surname> <given-names>DG</given-names></name>. <article-title>Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research</article-title>. <source>PLoS Biol</source>. <year>2010</year>;<volume>8</volume>: <fpage>e1000412</fpage> <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pbio.1000412" xlink:type="simple">10.1371/journal.pbio.1000412</ext-link></comment> <object-id pub-id-type="pmid">20613859</object-id></mixed-citation></ref>
<ref id="pone.0188859.ref018"><label>18</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lopez</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Ren</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Wei</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Lahat</surname> <given-names>G</given-names></name>, <etal>et al</etal>. <article-title>Combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma</article-title>. <source>Clin Cancer Res</source>. <year>2009</year>;<volume>15</volume>: <fpage>3472</fpage>–<lpage>83</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1158/1078-0432.CCR-08-2714" xlink:type="simple">10.1158/1078-0432.CCR-08-2714</ext-link></comment> <object-id pub-id-type="pmid">19417021</object-id></mixed-citation></ref>
<ref id="pone.0188859.ref019"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lopez</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Torres</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Hernandez</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Young</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Belousov</surname> <given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors</article-title>. <source>Cancer Res</source>. <year>2011</year>;<volume>71</volume>: <fpage>185</fpage>–<lpage>96</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1158/0008-5472.CAN-10-2799" xlink:type="simple">10.1158/0008-5472.CAN-10-2799</ext-link></comment> <object-id pub-id-type="pmid">21084276</object-id></mixed-citation></ref>
<ref id="pone.0188859.ref020"><label>20</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Buggy</surname> <given-names>JJ</given-names></name>, <name name-style="western"><surname>Cao</surname> <given-names>ZA</given-names></name>, <name name-style="western"><surname>Bass</surname> <given-names>KE</given-names></name>, <name name-style="western"><surname>Verner</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Balasubramanian</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>L</given-names></name>, <etal>et al</etal>. <article-title>CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo</article-title>. <source>Mol Cancer Ther</source> <year>2006</year>;<volume>5</volume>: <fpage>1309</fpage>–<lpage>17</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1158/1535-7163.MCT-05-0442" xlink:type="simple">10.1158/1535-7163.MCT-05-0442</ext-link></comment> <object-id pub-id-type="pmid">16731764</object-id></mixed-citation></ref>
<ref id="pone.0188859.ref021"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wagner</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>Hackanson</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Lubbert</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Jung</surname> <given-names>M</given-names></name>. <article-title>Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy</article-title>. <source>Clin Epigenetics</source>. <year>2010</year>;<volume>1</volume>: <fpage>117</fpage>–<lpage>36</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s13148-010-0012-4" xlink:type="simple">10.1007/s13148-010-0012-4</ext-link></comment> <object-id pub-id-type="pmid">21258646</object-id></mixed-citation></ref>
<ref id="pone.0188859.ref022"><label>22</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Aye</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Long</surname> <given-names>MJC</given-names></name>, <name name-style="western"><surname>Weiss</surname> <given-names>RS</given-names></name>. <article-title>Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies</article-title>. <source>Oncogene</source>. <year>2015</year>;<volume>34</volume>: <fpage>2011</fpage>–<lpage>21</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/onc.2014.155" xlink:type="simple">10.1038/onc.2014.155</ext-link></comment> <object-id pub-id-type="pmid">24909171</object-id></mixed-citation></ref>
<ref id="pone.0188859.ref023"><label>23</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Pastor-Anglada</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Pérez-Torras</surname> <given-names>S</given-names></name>. <article-title>Nucleoside transporter proteins as biomarkers of drug responsiveness and drug targets</article-title>. <source>Front Pharmacol</source>. <year>2015</year>;<volume>6</volume>: <fpage>13</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2015.00013" xlink:type="simple">10.3389/fphar.2015.00013</ext-link></comment> <object-id pub-id-type="pmid">25713533</object-id></mixed-citation></ref>
<ref id="pone.0188859.ref024"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Merimsky</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Meller</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Kollender</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Inbar</surname> <given-names>M</given-names></name>. <article-title>Palliative effect of gemcitabine in osteosarcoma resistant to standard chemotherapy</article-title>. <source>Eur J Cancer</source>. <year>1998</year>;<volume>34</volume>: <fpage>1296</fpage>–<lpage>7</lpage>. <object-id pub-id-type="pmid">9849496</object-id></mixed-citation></ref>
<ref id="pone.0188859.ref025"><label>25</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chatterjee</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Xiu</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Reddy</surname> <given-names>SK</given-names></name>, <name name-style="western"><surname>Jones</surname> <given-names>NL</given-names></name>, <name name-style="western"><surname>Buckley de Meritens</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Tergas</surname> <given-names>AI</given-names></name>, <etal>et al</etal>. <article-title>Uterine leiomyosarcomas exhibit distinct drug resistance molecular profiles compared to extrauterine leiomyosarcomas: A comprehensive analysis of 1,023 leiomyosarcomas</article-title>. <source>Gynecol Oncol</source>. <year>2016</year>;<volume>141</volume>(<issue>Supp 1</issue>):<fpage>51</fpage>–<lpage>2</lpage>.</mixed-citation></ref>
<ref id="pone.0188859.ref026"><label>26</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sampson</surname> <given-names>ER</given-names></name>, <name name-style="western"><surname>Amin</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Schwarz</surname> <given-names>EM</given-names></name>, <name name-style="western"><surname>O’Keefe</surname> <given-names>RJ</given-names></name>, <name name-style="western"><surname>Rosier</surname> <given-names>RN</given-names></name>. <article-title>The histone deacetylase inhibitor vorinostat selectively sensitizes fibrosarcoma cells to chemotherapy</article-title>. <source>J Orthop Res</source>. <year>2011</year>;<volume>29</volume>: <fpage>623</fpage>–<lpage>32</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/jor.21274" xlink:type="simple">10.1002/jor.21274</ext-link></comment> <object-id pub-id-type="pmid">20957741</object-id></mixed-citation></ref>
<ref id="pone.0188859.ref027"><label>27</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lee</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>McGuire</surname> <given-names>C</given-names></name>. <article-title>Clinical efficacy of Vorinostat in a patient with leiomyosarcoma</article-title>. <source>Clin Med Insights Oncol</source>. <year>2012</year>;<volume>6</volume>: <fpage>101</fpage>–<lpage>5</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.4137/CMO.S7194" xlink:type="simple">10.4137/CMO.S7194</ext-link></comment> <object-id pub-id-type="pmid">22408374</object-id></mixed-citation></ref>
<ref id="pone.0188859.ref028"><label>28</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rundall</surname> <given-names>BK</given-names></name>, <name name-style="western"><surname>Denlinger</surname> <given-names>CE</given-names></name>, <name name-style="western"><surname>Jones</surname> <given-names>DR</given-names></name>. <article-title>Suberoylanilide hydroxamic acid combined with gemcitabine enhances apoptosis in non-small cell lung cancer</article-title>. <source>Surgery</source>. <year>2005</year>;<volume>138</volume>: <fpage>360</fpage>–<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.surg.2005.06.016" xlink:type="simple">10.1016/j.surg.2005.06.016</ext-link></comment> <object-id pub-id-type="pmid">16153448</object-id></mixed-citation></ref>
<ref id="pone.0188859.ref029"><label>29</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Piacentini</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Donadelli</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Costanzo</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Moore</surname> <given-names>PS</given-names></name>, <name name-style="western"><surname>Palmieri</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Scarpa</surname> <given-names>A</given-names></name>. <article-title>Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation</article-title>. <source>Virchows Arch</source>. <year>2006</year>;<volume>448</volume>: <fpage>797</fpage>–<lpage>804</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s00428-006-0173-x" xlink:type="simple">10.1007/s00428-006-0173-x</ext-link></comment> <object-id pub-id-type="pmid">16568310</object-id></mixed-citation></ref>
<ref id="pone.0188859.ref030"><label>30</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Schniewind</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Heintz</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Kurdow</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Ammerpohl</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Trauzold</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Emme</surname> <given-names>D</given-names></name>, <etal>et al</etal>. <article-title>Combination phenylbutyrate/gemcitabine therapy effectively inhibits in vitro and in vivo growth of NSCLC by intrinsic apoptotic pathways</article-title>. <source>J Carcinog</source>. <year>2006</year>;<volume>5</volume>: <fpage>25</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/1477-3163-5-25" xlink:type="simple">10.1186/1477-3163-5-25</ext-link></comment> <object-id pub-id-type="pmid">17123441</object-id></mixed-citation></ref>
<ref id="pone.0188859.ref031"><label>31</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ammerpohl</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Trauzold</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Schniewind</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Griep</surname> <given-names>U</given-names></name>, <name name-style="western"><surname>Pilarsky</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Grutzmann</surname> <given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Complementary effects of HDAC inhibitor 4-PB on gap junction communication and cellular export mechanisms support restoration of chemosensitivity of PDAC cells</article-title>. <source>Br J Cancer</source>. <year>2007</year>;<volume>96</volume>: <fpage>73</fpage>–<lpage>81</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/sj.bjc.6603511" xlink:type="simple">10.1038/sj.bjc.6603511</ext-link></comment> <object-id pub-id-type="pmid">17164759</object-id></mixed-citation></ref>
<ref id="pone.0188859.ref032"><label>32</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Donadelli</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Costanzo</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Beghelli</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Scupoli</surname> <given-names>MT</given-names></name>, <name name-style="western"><surname>Dandrea</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Bonora</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Piacentini</surname> <given-names>P</given-names></name>, <etal>et al</etal>. <article-title>Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine</article-title>. <source>Biochim Biophys Acta</source>. <year>2007</year>;<volume>1773</volume>: <fpage>1095</fpage>–<lpage>106</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.bbamcr.2007.05.002" xlink:type="simple">10.1016/j.bbamcr.2007.05.002</ext-link></comment> <object-id pub-id-type="pmid">17555830</object-id></mixed-citation></ref>
<ref id="pone.0188859.ref033"><label>33</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Iwahashi</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Shimada</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Utsunomiya</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Morine</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Imura</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Ikemoto</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Mori</surname> <given-names>H</given-names></name>, <etal>et al</etal>. <article-title>Histone deacetylase inhibitor augments anti-tumor effect of gemcitabine and pegylated interferon-α on pancreatic cancer cells</article-title>. <source>Int J Clin Oncol</source>. <year>2011</year>;<volume>16</volume>: <fpage>671</fpage>–<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s10147-011-0246-y" xlink:type="simple">10.1007/s10147-011-0246-y</ext-link></comment> <object-id pub-id-type="pmid">21556798</object-id></mixed-citation></ref>
<ref id="pone.0188859.ref034"><label>34</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Iwahashi</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Shimada</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Utsunomiya</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Morine</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Imura</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Ikemoto</surname> <given-names>T</given-names></name>, <etal>et al</etal>. <article-title>Histone deacetylase inhibitor enhances the anti-tumor effect of gemcitabine: a special reference to gene-expression microarray analysis</article-title>. <source>Oncol Rep</source>. <year>2011</year>;<volume>26</volume>: <fpage>1057</fpage>–<lpage>62</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3892/or.2011.1407" xlink:type="simple">10.3892/or.2011.1407</ext-link></comment> <object-id pub-id-type="pmid">21805043</object-id></mixed-citation></ref>
<ref id="pone.0188859.ref035"><label>35</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dovzhanskiy</surname> <given-names>DI</given-names></name>, <name name-style="western"><surname>Arnold</surname> <given-names>SM</given-names></name>, <name name-style="western"><surname>Hackert</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Oehme</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Witt</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Felix</surname> <given-names>K</given-names></name>, <etal>et al</etal>. <article-title>Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer</article-title>. <source>BMC Cancer</source>. <year>2012</year>;<volume>812</volume>: <fpage>226</fpage>.</mixed-citation></ref>
<ref id="pone.0188859.ref036"><label>36</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Klein</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>Henke</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Sauer</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Bessler</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Reiners</surname> <given-names>KS</given-names></name>, <name name-style="western"><surname>Engert</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>The histone deacetylase inhibitor LBH589 (panobinostat) modulates the crosstalk of lymphocytes with Hodgkin lymphoma cell lines</article-title>. <source>PLoS One</source>. <year>2013</year>;<volume>8</volume>: <fpage>e79502</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0079502" xlink:type="simple">10.1371/journal.pone.0079502</ext-link></comment> <object-id pub-id-type="pmid">24278143</object-id></mixed-citation></ref>
<ref id="pone.0188859.ref037"><label>37</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Minjie</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Defei</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Zhimin</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Weiding</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Yuhua</surname> <given-names>Z</given-names></name>. <article-title>Targeting pancreatic cancer cells by a novel hydroxamate-based histone deacetylase (HDAC) inhibitor ST-3595</article-title>. <source>Tumour Biol</source>. <year>2015</year>;<volume>36</volume>: <fpage>9015</fpage>–<lpage>22</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s13277-015-3537-5" xlink:type="simple">10.1007/s13277-015-3537-5</ext-link></comment> <object-id pub-id-type="pmid">26084607</object-id></mixed-citation></ref>
<ref id="pone.0188859.ref038"><label>38</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Xue</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Gu</surname> <given-names>JJ</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>Q</given-names></name>, <name name-style="western"><surname>Mavis</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Hernandez-Ilizaliturri</surname> <given-names>FJ</given-names></name>, <name name-style="western"><surname>Czuczman</surname> <given-names>MS</given-names></name>, <etal>et al</etal>. <article-title>Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents</article-title>. <source>J Cancer Res Clin Oncol</source>. <year>2016</year>;<volume>142</volume>: <fpage>379</fpage>–<lpage>87</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s00432-015-2026-y" xlink:type="simple">10.1007/s00432-015-2026-y</ext-link></comment> <object-id pub-id-type="pmid">26314218</object-id></mixed-citation></ref>
<ref id="pone.0188859.ref039"><label>39</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sakamoto</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Kobayashi</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Yamada</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Nagano</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Tomokuni</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Tomimaru</surname> <given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>A histone deacetylase inhibitor suppresses epithelial-mesenchymal transition and attenuates chemoresistance in biliary tract cancer</article-title>. <source>PLoS One</source>. <year>2016</year>;<volume>11</volume>: <fpage>e0145985</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0145985" xlink:type="simple">10.1371/journal.pone.0145985</ext-link></comment> <object-id pub-id-type="pmid">26726879</object-id></mixed-citation></ref>
<ref id="pone.0188859.ref040"><label>40</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Henderson</surname> <given-names>SE</given-names></name>, <name name-style="western"><surname>Ding</surname> <given-names>LY</given-names></name>, <name name-style="western"><surname>Mo</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Bekaii-Saab</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Kulp</surname> <given-names>SK</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>CS</given-names></name>, <etal>et al</etal>. <article-title>Suppression of tumor growth and muscle wasting in a transgenic mouse model of pancreatic cancer by the novel histone deacetylase inhibitor AR-42</article-title>. <source>Neoplasia</source>. <year>2016</year>;<volume>18</volume>: <fpage>765</fpage>–<lpage>774</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.neo.2016.10.003" xlink:type="simple">10.1016/j.neo.2016.10.003</ext-link></comment> <object-id pub-id-type="pmid">27889645</object-id></mixed-citation></ref>
<ref id="pone.0188859.ref041"><label>41</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lee</surname> <given-names>HS</given-names></name>, <name name-style="western"><surname>Park</surname> <given-names>SB</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>SA</given-names></name>, <name name-style="western"><surname>Kwon</surname> <given-names>SK</given-names></name>, <name name-style="western"><surname>Cha</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Lee</surname> <given-names>DY</given-names></name>, <etal>et al</etal>. <article-title>A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance</article-title>. <source>Sci Rep</source>. <year>2017</year>;<volume>7</volume>: <fpage>41615</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/srep41615" xlink:type="simple">10.1038/srep41615</ext-link></comment> <object-id pub-id-type="pmid">28134290</object-id></mixed-citation></ref>
<ref id="pone.0188859.ref042"><label>42</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sung</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Richard</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Brady</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Maier</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Kelter</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Heise</surname> <given-names>C</given-names></name>. <article-title>Histone deacetylase inhibitor MGCD0103 synergizes with gemcitabine in human pancreatic cells</article-title>. <source>Cancer Sci</source>. <year>2011</year>;<volume>102</volume>: <fpage>1201</fpage>–<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1349-7006.2011.01921.x" xlink:type="simple">10.1111/j.1349-7006.2011.01921.x</ext-link></comment> <object-id pub-id-type="pmid">21375679</object-id></mixed-citation></ref>
<ref id="pone.0188859.ref043"><label>43</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Samulitis</surname> <given-names>BK</given-names></name>, <name name-style="western"><surname>Pond</surname> <given-names>KW</given-names></name>, <name name-style="western"><surname>Pond</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Cress</surname> <given-names>AE</given-names></name>, <name name-style="western"><surname>Patel</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Wisner</surname> <given-names>L</given-names></name>, <etal>et al</etal>. <article-title>Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors</article-title>. <source>Cancer Biol Ther</source>. <year>2015</year>;<volume>16</volume>: <fpage>43</fpage>–<lpage>51</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.4161/15384047.2014.986967" xlink:type="simple">10.4161/15384047.2014.986967</ext-link></comment> <object-id pub-id-type="pmid">25485960</object-id></mixed-citation></ref>
<ref id="pone.0188859.ref044"><label>44</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lee</surname> <given-names>HS</given-names></name>, <name name-style="western"><surname>Park</surname> <given-names>SB</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>SA</given-names></name>, <name name-style="western"><surname>Kwon</surname> <given-names>SK</given-names></name>, <name name-style="western"><surname>Cha</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Lee</surname> <given-names>DY</given-names></name>, <etal>et al</etal>. <article-title>A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance</article-title>. <source>Sci Rep</source>. <year>2017</year>;<volume>30</volume>: <fpage>41615</fpage>.</mixed-citation></ref>
<ref id="pone.0188859.ref045"><label>45</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cen</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Youn</surname> <given-names>DY</given-names></name>, <name name-style="western"><surname>Sauve</surname> <given-names>AA</given-names></name>. <article-title>Advances in characterization of human sirtuin isoforms: chemistries, targets and therapeutic applications</article-title>. <source>Curr Med Chem</source>. <year>2011</year>;<volume>18</volume>: <fpage>1919</fpage>–<lpage>35</lpage>. <object-id pub-id-type="pmid">21517779</object-id></mixed-citation></ref>
<ref id="pone.0188859.ref046"><label>46</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Candelaria</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>de la Cruz-Hernández</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Pérez-Cárdenas</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Trejo-Becerril</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Gutiérrez-Hernández</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Dueñas-González</surname> <given-names>A</given-names></name>. <article-title>Pharmacogenetics and pharmacoepigenetics of gemcitabine</article-title>. <source>Med Oncol</source>. <year>2010</year>;<volume>27</volume>: <fpage>1133</fpage>–<lpage>43</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s12032-009-9349-y" xlink:type="simple">10.1007/s12032-009-9349-y</ext-link></comment> <object-id pub-id-type="pmid">19902390</object-id></mixed-citation></ref>
<ref id="pone.0188859.ref047"><label>47</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Candelaria</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>de la Cruz-Hernandez</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Taja-Chayeb</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Perez-Cardenas</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Trejo-Becerril</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Gonzalez-Fierro</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>DNA methylation-independent reversion of gemcitabine resistance by hydralazine in cervical cancer cells</article-title>. <source>PLoS One</source>. <year>2012</year>;<volume>7</volume>: <fpage>e29181</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0029181" xlink:type="simple">10.1371/journal.pone.0029181</ext-link></comment> <object-id pub-id-type="pmid">22427797</object-id></mixed-citation></ref>
<ref id="pone.0188859.ref048"><label>48</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ansari</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Urey</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Hilmersson</surname> <given-names>KS</given-names></name>, <name name-style="western"><surname>Bauden</surname> <given-names>MP</given-names></name>, <name name-style="western"><surname>Ek</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Olsson</surname> <given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Apicidin sensitizes pancreatic cancer cells to gemcitabine by epigenetically regulating MUC4 expression</article-title>. <source>Anticancer Res</source>. <year>2014</year>;<volume>34</volume>: <fpage>5269</fpage>–<lpage>76</lpage>. <object-id pub-id-type="pmid">25275019</object-id></mixed-citation></ref>
<ref id="pone.0188859.ref049"><label>49</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hosokawa</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Saito</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Nakano</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Iwashita</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Ishizaka</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Ueda</surname> <given-names>K</given-names></name>, <etal>et al</etal>. <article-title>Acquired resistance to decitabine and cross-resistance to gemcitabine during the long-term treatment of human HCT116 colorectal cancer cells with decitabine</article-title>. <source>Oncol Lett</source>. <year>2015</year>;<volume>10</volume>: <fpage>761</fpage>–<lpage>767</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3892/ol.2015.3253" xlink:type="simple">10.3892/ol.2015.3253</ext-link></comment> <object-id pub-id-type="pmid">26622566</object-id></mixed-citation></ref>
</ref-list>
</back>
</article>